$12.05
-0.11 (-0.90%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CADL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
13 interventional · 1 with posted results
Held by 13 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, Point72 Asset Management, L.P., +8 more) · FINRA short interest 10.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)NCT07660094Overall SurvivalRandomized · Open-label · Treatment | Phase 3 | Recruiting | Biological: Aglatimagene Besadenovec, Pembrolizumab · Drug: Valacyclovir, Docetaxel | Non-squamous, Non-Small Cell Lung Cancer | 500 | 2031-10-22 | in 1,890 d | 2026-06-22 |
| A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecNCT07332000Biodistribution of aglatimagene besadenovecNon-randomized · Open-label · Basic science | Phase 2 | Recruiting | Biological: aglatimagene besadenovec + valacyclovir · Radiation: External Beam Radiation Therapy (EBRT) | Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma) | 45 | Aug 2026 | ≤ 12 d | 2026-03-20 |
| CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCNCT04495153Response rateOpen-label · Treatment | Phase 2 | Active, not recruiting | Biological: Aglatimagene besadenovec | Non Small Cell Lung Cancer | 90 | 2024-12-31actual | — | 2025-08-22 |
| Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)NCT02768363Progression-free survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Biological: aglatimagene besadenovec, placebo · Drug: valacyclovir | Prostate Cancer | 187 | Nov 2024actual | — | 2025-07-30 |
| Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerNCT01436968Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Biological: Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir | Prostate Cancer | 711 | Aug 2024actual | — | 2025-07-30 |
| Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaNCT02446093Safety grade by CTCAE version 4.0Randomized · Open-label · Treatment | Phase 2 | Unknown status | Biological: Aglatimagene besadenovec · Radiation: Chemoradiation, Stereotactic body radiation therapy · Procedure: Surgery | Borderline Resectable Pancreatic Adenocarcinoma | 54 | Dec 2025 | — | 2024-01-08 |
| GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade GliomasNCT03576612Incidence of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: AdV-tk, Nivolumab · Drug: Valacyclovir, Temozolomide · Radiation · Other: Laboratory Biomarker Analysis | Glioma, Malignant | 41 | 2023-06-30actual | — | 2025-02-14 |
| Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung CancerNCT03131037Incidence of treatment emergent adverse eventsOpen-label · Treatment | Phase 1 | Completed | Biological: CAN-2409 + valacyclovir | Lung Cancer | 12 | 2021-12-01actual | — | 2025-07-11 |
| Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaNCT00589875results2024-04-03Number of Participants With Treatment Related Adverse EventsOpen-label · Treatment | Phase 2 | Completed | Biological: CAN-2409 · Drug: Valacyclovir, Temozolomide · Radiation: Radiation therapy | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma | 52 | Dec 2015actual | — | 2024-04-03 |
| A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain TumorsNCT00634231Incidence of treatment emergent adverse eventsOpen-label · Treatment | Phase 1 | Completed | Biological: AdV-tk · Drug: valacyclovir · Radiation | Malignant Glioma, Recurrent Ependymoma | 8 | Dec 2015actual | — | 2023-08-25 |
| Intrapleural AdV-tk Therapy in Patients With Malignant Pleural EffusionNCT01997190Incidence of treatment emergent adverse eventsOpen-label · Treatment | Phase 1 | Completed | Biological: AdV-tk + valacyclovir | Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer, Ovarian Cancer | 19 | Dec 2015actual | — | 2023-08-25 |
| AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)NCT00638612Incidence of treatment emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: AdV-tk · Drug: Valacyclovir | Pancreatic Adenocarcinoma, Pancreatic Cancer | 27 | May 2013actual | — | 2023-08-25 |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant GliomasNCT00751270Incidence of treatment emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: AdV-tk · Drug: Valacyclovir | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma | 15 | Jan 2010actual | — | 2023-08-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19